| 臺大學術典藏 |
2020-05-25T07:35:27Z |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
|
Lee J.-M; Yang S.-Y; Yang P.-W; Shun C.-T; Wu M.-T; Hsu C.-H; Chia-Chi Lin; Cheng J.-C.-H; Wang Y.-H; Chuang T.-H; Chen J.-S; Hsu H.-H; Huang P.-M; Kuo S.-W; Lee Y.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:27Z |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma
|
Tsai Y.-C; Hsu C.-H; Chia-Chi Lin; Hsu F.-M; Lee J.-M; Huang P.-M; Lee Y.-C; Chia-Hsien Cheng J. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W; Chia-Chi Lin; Huang T.-C; Cheng A.-L; Yeh K.-H; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer
|
Huang T.-C; Hsu C.-H; Chia-Chi Lin; Tu Y.-K. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C; Huang T.-C; Chia-Chi Lin; Hsieh M.-S; Chang C.-H; Huang P.-M; Lee J.-M; Hsu F.-M; Cheng J.C.-H; Wang H.-P; Yeh K.-H; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y; Cheng J.C.-H; Huang C.-Y; Tsai Y.-C; Chia-Chi Lin; Hsu C.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma
|
Yang P.-C; Guo J.-C; Hsieh M.-S; Chia-Chi Lin; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
|
Huang P.-M; Hsu F.-M; Chia-Chi Lin; Hsu C.-H; Cheng J.C.-H; Lee J.-M. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C; Chia-Chi Lin; Huang T.-C; Huang P.-M; Kuo H.-Y; Chang C.-H; Wang C.-C; Cheng J.C.-H; Yeh K.-H; Hsu C.-H; Lee J.-M. |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment
|
Cheng J.C.-H.;Hsieh M.-S;Chang Y.-L;Chia-Chi Lin;Hsu C.-H;Huang P.-M;Lee J.-M;Tsai C.-L;Hsu F.-M;Lu S.-L; Lu S.-L; Hsu F.-M; Tsai C.-L; Lee J.-M; Huang P.-M; Hsu C.-H; Chia-Chi Lin; Chang Y.-L; Hsieh M.-S; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C; Chia-Chi Lin; Wu Y.-C; Chia-Hsien Cheng J; Lee J.-M; Wang H.-P; Huang P.-M; Hsu F.-M; Yeh K.-H; Cheng A.-L; Tzen K.-Y; Hsu C.-H.; Hsu C.-H.;Tzen K.-Y;Cheng A.-L;Yeh K.-H;Hsu F.-M;Huang P.-M;Wang H.-P;Lee J.-M;Chia-Hsien Cheng J;Wu Y.-C;Chia-Chi Lin;Huang T.-C |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Chia-Chi Lin;Tajima N;Oguma T;Ishizuka T;Sugihara M;Chiu L.Y;Sasaki S.-I;Cheng A.-L;Yang J.C.-H;Yen Y.-H;Hsu C.-H;Chen T.W.-W;Lee J.-H; Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; Yang J.C.-H; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Bogenrieder T; Twelves C; Cheng A.-L.; Huang D.C.-L; Strelkowa N; Goeldner R.-G; Schmid U; Fuertig R; Buschke S; Jove M; Anthoney A; Yen C.-J; de Bono J; Chia-Chi Lin; Chen L.-T; Corral J; Michalarea V; Rihawi K; Ong M; Lee J.-H; Hsu C.-H; Yang J.C.-H; Shiah H.-S |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Yen-Shen Lu;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Yang C.H;Cheng A.L.; Yeh K.H; YEN-SHEN LU; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; Yang C.H; Cheng A.L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P;Wen C.-C;Hsiung C.A;Su I.-J;Cheng A.-L;Chang M.-C;Tsao C.-J;Kao W.-Y;Uen W.-C;Hsu C.-H;Yen-Shen Lu;Tien H.-F;Chao T.-Y;Chen L.-T;Whang-Peng J;Chen P.-J.; Su W.-P; Wen C.-C; Hsiung C.A; Su I.-J; Cheng A.-L; Chang M.-C; Tsao C.-J; Kao W.-Y; Uen W.-C; Hsu C.-H; YEN-SHEN LU; Tien H.-F; Chao T.-Y; Chen L.-T; Whang-Peng J; Chen P.-J. |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen P.-J; Cheng A.-L.; Hsieh H.-P; YEN-SHEN LU; Hsu C.-H; Hsu C; Yeh P.-Y; Cheng A.-L.;Chen P.-J;Hsieh H.-P;Yen-Shen Lu;Hsu C.-H;Hsu C;Yeh P.-Y;Chen K.-F; Chen K.-F |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma
|
Cheng A.-L.;Kuo M.-L;Chen C.-S;Feng W.-C;Lee W.-C;Chen K.-F;Hsu C.-H;Yen-Shen Lu;Yeh P.Y;Gao M; Gao M; Yeh P.Y; YEN-SHEN LU; Hsu C.-H; Chen K.-F; Lee W.-C; Feng W.-C; Chen C.-S; Kuo M.-L; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:01Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T;Yeh P.-Y;Gao M;Chen C.-W;Yeh L.-C;Feng W.-C;Kuo S.-H;Hsu C.-H;Yen-Shen Lu;Cheng A.-L.; Chiang C.-T; Yeh P.-Y; Gao M; Chen C.-W; Yeh L.-C; Feng W.-C; Kuo S.-H; Hsu C.-H; YEN-SHEN LU; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H;Hsu C.-H;Chen L.-T;Yen-Shen Lu;Lin C.-H;Yeh P.-Y;Jeng H.-J;Gao M;Yeh K.-H;Cheng A.-L.; Kuo S.-H; Hsu C.-H; Chen L.-T; YEN-SHEN LU; Lin C.-H; Yeh P.-Y; Jeng H.-J; Gao M; Yeh K.-H; Cheng A.-L. |
